Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study

PLoS One. 2022 Jul 1;17(7):e0270512. doi: 10.1371/journal.pone.0270512. eCollection 2022.

Abstract

Background and aims: The aim of this study was to evaluate the diagnostic value of FibroTouch and serological models on staging hepatic fibrosis in chronic liver diseases.

Methods: We recruited 850 patients undergoing liver biopsy and received FibroTouch test before or after liver biopsy within one week, blood was taken for the routine inspection before the operation within one week. The serological models were calculated by the blood results and routine clinical information. The diagnostic value of FibroTouch and six serological models was analyzed by receiver operating characteristic curve (ROC).

Results: Patients with severe liver fibrosis had significantly higher AST, ALT, GGT, RDW, ALP, and FT-LSM. The area under the receiver operating characteristic curve (AUROC) of FT-LSM for the liver diagnosis of S≥2, S≥3 and S = 4 was 0.75(95% confidence interval [CI]:0.72-0.78), 0.83(95% CI: 0.80-0.86), and 0.85 (95% CI: 0.81-0.89), respectively. The optimal cut-off of FT-LSM for diagnosing S≥2, S≥3 and S = 4 was 8.7, 10.7, and 12.3, respectively.

Conclusions: Our study showed the FibroTouch has a higher diagnostic value compared with the non-invasive serological models in staging the fibrosis stage. The cut-off of FibroTouch and five serological models (APRI, FIB-4, S-index, Forns, and PRP) increased with the severe of fibrosis stage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chronic Disease
  • Graft vs Host Disease*
  • Humans
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / pathology
  • Liver Diseases*
  • ROC Curve
  • Retrospective Studies

Grants and funding

This research was funded by Hangzhou agricultural and social development scientific research (20201203B179) and General projects of Hangzhou health science and technology plan in 2020 (A20200157). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.